TEVA Teva Pharmaceutical Industries Limited
XNYS
40.00
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
TEVA
$40.00
—
Key stats
$40.00
Pre-market
$39.98
-1.02%
- 52-Week Range
- $19.23 – $42.02
- YTD
- +29.24%
- IV Rank (30D)
- 65.13
- Straddle Price
- $4.05
- P/C Vol Ratio
- 1.05
- Market Cap
- $46.6B
- Open
- $39.71
- Day Range
- $39.71 – $40.86
- Volume
- 5,978,972
- Prev Close
- $39.95
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 0.99 |
| Cost of Equity (CAPM) | 9.91% (VRP-adj) |
| WACC | 8.88% |
| Volatility Risk Premium | +19.8pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +21.1% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $1.3B |
| Return on Equity (TTM) | 9.1% |
| Book / Price | 17.1% |
| Gross Margin (TTM) | 51.8% |
| FCF Margin (TTM) | 7.8% |
| Debt / Equity | 1.89 |
| Quality Score | 2/6 — normal (10y DCF) |
| Market-Implied Growth | +19.4% (reverse-DCF on current price) |
| SMA 50 | $38.75 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $40.23 |
| Bollinger Width / SMA20 | 20.1% (drives anchor stability) |
| Net Debt | $11.4B |
| Market Cap | $46B |
Peers used for multiples: ABBV, BMY, GSK, INSM, LLY, MRK, NVO, NVS
60-Day Conviction
55%
20-Day Fair Value
≈ by Nov 25, 2026
$40.88
α +1.2%
rank 62%
conviction
67%
40-Day Fair Value
≈ by Dec 24, 2026
$41.06
α +1.7%
rank 63%
conviction
55%
60-Day Fair Value
≈ by Jan 22, 2027
$41.06
α +1.7%
rank 56%
conviction
55%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $45.03 | 22% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $56.11 | 7% | median 42.5× · 5 peers |
| Peer EV/EBITDA | $100.34 | 7% | median 23.6× · 5 peers |
| Peer P/B | $58.24 | 7% | median 8.6× · 5 peers |
| Peer P/S | $111.20 | 7% | median 6.8× · 6 peers |
| Market Anchor (SMA50) | $38.75 | 30% | stability 66% (BB-width) |
| Options Expected (B-L 30d) | $40.31 | 21% | 19 strikes · skew +0.48 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNYS
- Market Cap
- $46.6B
- Employees
- 32,842
- List Date
- 1982-02-16
- CIK
- 0000818686
- Next Earnings
- 2026-11-03 (Pre-Market)
- EPS Forecast
- $0.70 (4 est.)
- Headquarters
- Tel Aviv
- Homepage
- https://www.tevapharm.com
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distribut…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 13.93% | 1.20% | 10.60% | 13.40% | -16.76% | 10.11% | 5.41% |
| Feb | -10.41% | -6.66% | -6.51% | 5.54% | -5.13% | -4.67% | -4.64% |
| Mar | 5.68% | 20.54% | -12.20% | 4.52% | -3.94% | -10.81% | 0.63% |
| Apr | -6.79% | -7.24% | -4.28% | 1.01% | 1.44% | 15.93% | 0.01% |
| May | -3.79% | 6.68% | -18.55% | 21.10% | 7.43% | 1.06% | 2.32% |
| Jun | -5.71% | -19.40% | 4.58% | -4.30% | -2.90% | -2.19% | -4.99% |
| Jul | -2.72% | 18.88% | 12.30% | 6.67% | -7.15% | 3.67% | 5.27% |
| Aug | -4.37% | -4.64% | 17.73% | 7.58% | 19.51% | 4.61% | 6.74% |
| Sep | 3.84% | -9.63% | 3.66% | -2.70% | 7.73% | 9.42% | 2.05% |
| Oct | -9.90% | 8.38% | -14.29% | 4.36% | 2.09% | 2.75%* | -1.10% |
| Nov | -10.62% | -3.84% | 12.10% | -9.05% | 31.04% | -- | 3.93% |
| Dec | -2.08% | 4.83% | 7.52% | 32.37% | 16.80% | -- | 11.89% |
| Total | -30.52% | 1.65% | 4.80% | 105.43% | 49.94% | 30.81% | 27.02% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $40.26
SMA 50: $38.83
SMA 200: $34.45
Current: $40.39
EMA 12: $40.33
EMA 26: $39.89
MACD: 0.4430 | Signal: -0.1988
BULLISH
ADX (14): 23.77
WEAK TREND
+DI: 21.83
−DI: 18.42
Momentum Oscillators
RSI (14): 54.38
NEUTRAL
Stoch %K: 44.21
Stoch %D: 45.12
Williams %R: -43.24
Volume & Volatility
BB Upper: $41.88
BB Lower: $38.64
NEUTRAL
OBV: 338,172,159
Vol SMA 20: 6,237,344
Vol ROC: -12.43%
ATR: $1.11
True Range: $1.15
HV 20: 22.3%
HV 30: 25.9%
HV 60: 26.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-29T00:00:00 – 2026-10-27T00:00:00
AI Analysis
Here is a comprehensive stock analysis report for TEVA:
Executive Summary
Overall assessment: NEUTRAL (confidence level 6/10) Key drivers and primary risks:
- Technical signals indicate a range-bound market with potential for breakout/breakdown
- Recent news headlines suggest positive developments, but sentiment is mixed
- Volatility is moderate, indicating a relatively stable market
Two-sentence investment thesis: TEVA's biosimilar business is driving growth, but the company still faces challenges in its generics and specialty segments. A potential break above the upper Bollinger Band could trigger further upside.
Recent news sentiment impact: The positive news headlines on TEVA's biosimilar submissions and earnings releases have contributed to a generally upbeat sentiment, although some concerns remain around the company's generics and specialty divisions.
Technical Analysis
Trend Direction: Range-bound (short-term), Neutral (medium-term), Bullish (long-term) Support/Resistance Levels:
- Upper Bollinger Band: $35.23
- Middle line: $33.19
- Lower Bollinger Band: $31.15
Momentum Signals:
- RSI interpretation: Neutral (38.19) with no clear buy/sell signal
- MACD signal: Bearish (histogram -0.14)
- Bollinger Bands position: Neutral (signal line in the middle)
Volume Analysis:
- Volume SMA 20: 5590871.60
- On-Balance Volume (OBV): 313702984.32
- Volume Rate of Change: 2.28%
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines highlight TEVA's biosimilar submissions, earnings releases, and product launches, which have contributed to a generally positive sentiment.
Sentiment Assessment: Aggregate news sentiment is NEUTRAL, with some positive developments balanced by concerns around the company's generics and specialty segments.
Catalyst Identification: TEVA has submitted several biosimilar applications, which could lead to significant growth if approved. The company also faces earnings release dates, which could impact stock price.
Market Narrative: The recent news headlines align somewhat with the technical signals, which suggest a range-bound market with potential for breakout/breakdown. However, the mixed sentiment and moderate volatility indicate that further analysis is needed to determine the next move.
Risk & Volatility Assessment
Risk Assessment: Moderate (beta 0.85, IV premium 64.2%) Volatility Regime: Current vs historical volatility levels indicate a relatively stable market. Options Market Signals:
- IV Rank: 41.4% (Medium)
- Current IV: 63.5%
- Expected Move: $3.62 (30 DTE), 7-DTE: $1.55
- Volume Flow: 92 calls vs 25 puts
- Open Interest: 178 calls vs 16 puts
Downside Protection: Support levels include the lower Bollinger Band ($31.15) and the SMA 200 ($29.98). Risk management considerations include setting stop-loss levels below these support levels.
Market Context & Positioning
Sector Performance: TEVA is outperforming its sector peers, with a relative strength index (RSI) of 0.58.
Institutional Activity: Volume patterns suggest institutional interest, with a volume rate of change of 2.28%.
Correlation Analysis: TEVA's correlation with the market (R-squared interpretation) is 0.27, indicating a moderate degree of correlation.
Relative Valuation: TEVA's valuation relative to its trading range suggests that it may be undervalued or overvalued depending on the specific level.
Key Levels & Action Items
Critical Price Levels:
- Upper Bollinger Band: $35.23
- Middle line: $33.19
- Lower Bollinger Band: $31.15
Breakout/Breakdown Levels:
- SMA 50: $34.07
- EMA 12: $32.93
Time-Sensitive Catalysts: Earnings release dates and biosimilar application submissions could impact stock price.
Risk Management: Stop-loss levels should be set below the support levels (lower Bollinger Band, SMA 200), with position sizing considerations based on volatility and risk tolerance.
Generated
News
All TEVA news →
Teva stock surged Friday after the FDA approved its schizophrenia drug, a once-monthly injectable treatment for the disease. The post Teva, Already Up 26% This Year, Surges Again On First-Of-Its-Kind Approval appeared first on Investor's Business Daily .
Showing 1–10 of 12
Page 1 of 2
Earnings History
15 of 23 under expected move
Avg Expected Move
7.99%
Avg Actual Move
7.22%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-10 | Pre-Market | 7.73% | 6.95% | 0.90x | Within |
| 2021-04-28 | Pre-Market | 7.52% | 2.41% | 0.32x | Within |
| 2021-07-28 | Pre-Market | 7.06% | 12.00% | 1.70x | Exceeded |
| 2021-10-27 | Pre-Market | 7.67% | 4.90% | 0.64x | Within |
| 2022-02-09 | Pre-Market | 8.69% | 8.44% | 0.97x | Within |
| 2022-05-03 | Pre-Market | 8.21% | 0.82% | 0.10x | Within |
| 2022-07-26 | Pre-Market | 6.95% | 0.97% | 0.14x | Within |
| 2022-11-03 | Pre-Market | 7.88% | 1.71% | 0.22x | Within |
| 2023-02-08 | Pre-Market | 6.98% | 8.91% | 1.28x | Exceeded |
| 2023-05-10 | Pre-Market | 6.15% | 8.24% | 1.34x | Exceeded |
| 2023-08-02 | Pre-Market | 7.84% | 11.58% | 1.48x | Exceeded |
| 2023-11-08 | Pre-Market | 8.74% | 1.22% | 0.14x | Within |
| 2024-01-31 | Pre-Market | 8.70% | 3.15% | 0.36x | Within |
| 2024-05-08 | Pre-Market | 7.38% | 12.83% | 1.74x | Exceeded |
| 2024-07-31 | Pre-Market | 9.99% | 6.22% | 0.62x | Within |
| 2024-11-06 | Pre-Market | 7.86% | 7.14% | 0.91x | Within |
| 2025-01-29 | Pre-Market | 7.50% | 13.89% | 1.85x | Exceeded |
| 2025-05-07 | Pre-Market | 9.21% | 9.18% | 1.00x | Within |
| 2025-07-30 | Pre-Market | 8.22% | 1.75% | 0.21x | Within |
| 2025-11-05 | Pre-Market | 6.99% | 20.23% | 2.89x | Exceeded |
| 2026-01-28 | Pre-Market | 6.90% | 2.09% | 0.30x | Within |
| 2026-04-29 | Pre-Market | 12.18% | 11.89% | 0.98x | Within |
| 2026-07-29 | Pre-Market | 7.45% | 9.60% | 1.29x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
TEVA Options Activity & IV Rank
TEVA IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 44.2%
7-DTE IV: 59.2%
Expected Move: $4.05
7-DTE Move: $3.31
Days to Exp: 31 (2026-11-27)
Options Flow
Call Volume: 111
Put Volume: 117
P/C Volume: 1.054
NEUTRAL
Call OI: 276
Put OI: 121
P/C OI: 0.438
Total OI: 397
ATM Options Pricing
ATM Call: $2.26
ATM Put: $1.79
Call %: 5.6%
Put %: 4.5%
Chain Summary
Chain Volume: 19,055
Chain OI: 287,801
Last Updated: 10/27/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 91st percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
91%
vs own history
GEX tilt
+0.65
OI-weighted, today
Vanna tilt
+0.62
δ-sensitivity to IV
Charm tilt
-0.51
δ-decay vs time
Vanna tilt +0.62: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.51: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 124 ATM contracts, 147k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
100%
+24.5
pts
EXTREME
as of Oct 27 · ATM 51.6% / Wing 76.1%
30 DTE / 10d
32%
+3.8
pts
EXTREME
as of Oct 27 · ATM 43.8% / Wing 47.6%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)52.7MediumOct 27
IV Rank (30 DTE)65.1MediumOct 27
Straddle Price (30 DTE)$4.05Oct 27
Beta Analysis
Risk Metrics
Beta: 0.7510
Alpha: 70.52%
Correlation: 0.2448
R-Squared: 6.0%
Stock Volatility: 39.0%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own TEVA
7 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Glenview Capital Hedge fund Larry Robbins | $172.1M | #10 of 42 | -23.7% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $110.6M | #304 of 3716 | +72.4% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $44.9M | #89 of 997 | +17.6% | 13F | |
| Point72 Hedge fund Steve Cohen | $35.9M | #418 of 1945 | -6.3% | 13F | |
| Duquesne Family Office Family office Stanley Druckenmiller | $21.2M | #46 of 86 | -73.7% | 13F | |
| Citadel Hedge fund Ken Griffin | $2.5M | #2700 of 6285 | new | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $390K | #2219 of 4729 | -18.0% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
TEVA Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 1,161,750,000 (as of 2025-12-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
32 filers$725.16M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $274.66M | 37.88% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $95.61M | 13.18% | 2026-06-30 |
| 3 | Walleye Trading LLC | $84.97M | 11.72% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $53.14M | 7.33% | 2026-06-30 |
| 5 | Caption Management, LLC | $43.35M | 5.98% | 2026-06-30 |
| 6 | PICTON MAHONEY ASSET MANAGEMENT | $33.88M | 4.67% | 2026-06-30 |
| 7 | Millennium Management LLC Custodian | $23.28M | 3.21% | 2026-06-30 |
| 8 | Capital Markets Trading UK LLP | $23.10M | 3.18% | 2026-06-30 |
| 9 | IMC-Chicago, LLC Custodian | $17.88M | 2.46% | 2026-06-30 |
| 10 | GROUP ONE TRADING LLC Custodian | $15.41M | 2.12% | 2026-06-30 |
| 11 | Simplex Trading, LLC Custodian | $11.69M | 1.61% | 2026-06-30 |
| 12 | Walleye Capital LLC | $8.10M | 1.12% | 2026-06-30 |
| 13 | Clal Insurance Enterprises Holdings Ltd | $6.25M | 0.86% | 2026-06-30 |
| 14 | CMT Capital Markets Trading GmbH | $4.87M | 0.67% | 2026-06-30 |
| 15 | Balyasny Asset Management L.P. | $4.29M | 0.59% | 2026-06-30 |
| 16 | Wolverine Trading, LLC Custodian | $4.15M | 0.57% | 2025-09-30 |
| 17 | Point72 Asset Management, L.P. | $3.56M | 0.49% | 2026-06-30 |
| 18 | Atika Capital Management LLC | $3.39M | 0.47% | 2026-06-30 |
| 19 | PEAK6 LLC | $2.54M | 0.35% | 2026-06-30 |
| 20 | JPMorgan Chase & Co Custodian | $1.95M | 0.27% | 2026-06-30 |
| 21 | CAPITAL FUND MANAGEMENT S.A. | $1.92M | 0.26% | 2026-06-30 |
| 22 | Centiva Capital, LP | $1.69M | 0.23% | 2026-06-30 |
| 23 | UBS Group AG Custodian | $1.36M | 0.19% | 2026-06-30 |
| 24 | Squarepoint Ops LLC | $1.15M | 0.16% | 2026-06-30 |
| 25 | TUDOR INVESTMENT CORP ET AL | $945.25K | 0.13% | 2026-06-30 |
26 filers$372.99M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $149.27M | 40.02% | 2026-06-30 |
| 2 | Walleye Trading LLC | $48.31M | 12.95% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $45.66M | 12.24% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $25.88M | 6.94% | 2026-06-30 |
| 5 | Caption Management, LLC | $22.85M | 6.13% | 2026-06-30 |
| 6 | Capital Markets Trading UK LLP | $14.70M | 3.94% | 2026-06-30 |
| 7 | Point72 Asset Management, L.P. | $13.52M | 3.63% | 2026-06-30 |
| 8 | IMC-Chicago, LLC Custodian | $10.63M | 2.85% | 2026-06-30 |
| 9 | Simplex Trading, LLC Custodian | $6.15M | 1.65% | 2026-06-30 |
| 10 | GROUP ONE TRADING LLC Custodian | $5.18M | 1.39% | 2026-06-30 |
| 11 | Wolverine Trading, LLC Custodian | $4.17M | 1.12% | 2025-09-30 |
| 12 | Walleye Capital LLC | $3.87M | 1.04% | 2026-06-30 |
| 13 | PEAK6 LLC | $3.39M | 0.91% | 2026-06-30 |
| 14 | CAPITAL FUND MANAGEMENT S.A. | $3.15M | 0.84% | 2026-06-30 |
| 15 | CMT Capital Markets Trading GmbH | $2.88M | 0.77% | 2026-06-30 |
| 16 | TUDOR INVESTMENT CORP ET AL | $2.72M | 0.73% | 2026-06-30 |
| 17 | Crawford Fund Management, LLC | $2.47M | 0.66% | 2026-06-30 |
| 18 | Verition Fund Management LLC | $1.73M | 0.47% | 2026-06-30 |
| 19 | JPMorgan Chase & Co Custodian | $1.67M | 0.45% | 2026-06-30 |
| 20 | CONTINENTAL ADVISORS LLC | $1.58M | 0.42% | 2026-09-30 |
| 21 | Millennium Management LLC Custodian | $897.82K | 0.24% | 2026-06-30 |
| 22 | Balyasny Asset Management L.P. | $884.27K | 0.24% | 2026-06-30 |
| 23 | Two Sigma Investments, LP Custodian | $816.51K | 0.22% | 2026-06-30 |
| 24 | SUMMIT SECURITIES GROUP LLC | $338.80K | 0.09% | 2026-06-30 |
| 25 | Squarepoint Ops LLC | $250.71K | 0.07% | 2026-06-30 |
TEVA Insider Trading (Form 4)
Latest: 2026-09-22Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-22 | Roberto Mignone | Director | Sell (S) | −367,600 | $39.06 | -$14.36M | EDGAR |
| 2026-09-22 | Brian Savage | Interim Chief Legal Officer | Mixed | −2,839 | $37.27 | -$129.0K | EDGAR |
| 2026-08-25 | Ronit Satchi-Fainaro | Director | Sell (S) | −415 | $37.25 | -$15.5K | EDGAR |
| 2026-08-25 | Amir Weiss | Chief Accounting Officer | Mixed | −6,945 | $33.85 | -$306.3K | EDGAR |
| 2026-08-19 | Evan Lippman | EVP, Business Development | Sell (S) | −18,600 | $36.57 | -$680.3K | EDGAR |
| 2026-08-10 | Tal Zvi Zaks | Director | Sell (S) | −17 | $34.87 | -$593 | EDGAR |
| 2026-08-05 | Eric A Hughes | See "Remarks" | Mixed | +27,166 | $34.88 | -$892.1K | EDGAR |
| 2026-08-05 | Placid Jover | See "Remarks" | Mixed | — | $34.88 | -$447.4K | EDGAR |
| 2026-06-22 | Matthew Shields | EVP, Global Operations | Sell (S) | −9,989 | $32.19 | -$321.5K | EDGAR |
| 2026-06-16 | Eliyahu Sharon Kalif | EVP, Chief Financial Officer | Sell (S) | −106,563 | $34.10 | -$3.63M | EDGAR |
| 2026-06-08 | Ronit Satchi-Fainaro | Director | Exer (M) | +14,492 | — | EDGAR | |
| 2026-06-08 | Amir Elstein | Director | Exer (M) | +14,492 | — | EDGAR | |
| 2026-06-08 | Tal Zvi Zaks | Director | Exer (M) | +14,492 | — | EDGAR | |
| 2026-06-08 | Gerald M Lieberman | Director | Exer (M) | +14,492 | — | EDGAR | |
| 2026-06-08 | Perry Nisen | Director | Exer (M) | +14,492 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
TEVA Insider Holdings
22 insiders · @ $40.39
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Amir Elstein | Director | 2,118,455 | $85.56M | $0 | 19 | 2026-06-08 |
| 2 | Richard D Francis | President and CEO | 1,177,529 | $47.56M | -$34.82M | 15 | 2026-06-08 |
| 3 | Sol J Barer | Director | 448,011 | $18.10M | $2.00M | 22 | 2026-06-08 |
| 4 | Eric A Hughes | See "Remarks" | 134,877 | $5.45M | -$7.49M | 15 | 2026-08-05 |
| 5 | Gerald M Lieberman | Director | 130,149 | $5.26M | $0 | 19 | 2026-06-08 |
| 6 | Rosemary A Crane | Director | 127,739 | $5.16M | -$34.0K | 19 | 2026-06-08 |
| 7 | Roberto Mignone | Director | 119,807 | $4.84M | -$23.52M | 24 | 2026-09-22 |
| 8 | Perry Nisen | Director | 119,807 | $4.84M | $0 | 17 | 2026-06-08 |
| 9 | Ronit Satchi-Fainaro | Director | 111,986 | $4.52M | -$15.5K | 17 | 2026-08-25 |
| 10 | Mark Sabag | See "Remarks" | 80,760 | $3.26M | -$25.95M | 38 | 2026-05-04 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
TEVA Board & Officers
As of SEC filings through Oct 8, 2026Directors 11
- Amir Elstein · since Jan 1, 2018
- Gerald M Lieberman · since Jan 1, 2018
- Perry Nisen · since Jan 1, 2018
- Roberto Mignone · since Jan 1, 2018
- Rosemary A Crane · since Jan 1, 2018
- Sol J Barer · since Jan 1, 2018
- Ronit Satchi-Fainaro · since Jun 5, 2018
- Janet S. Vergis · since Jun 9, 2020
- Tal Zvi Zaks · since Oct 1, 2021
- Varda Shalev · since Sep 1, 2023
- Chen Lichtenstein · since Dec 1, 2024
Officers 12
- Richard D Francis · President and CEO · since Jan 1, 2023
- Eliyahu Sharon Kalif · EVP, Chief Financial Officer · since Dec 22, 2019
- Amir Weiss · Chief Accounting Officer · since Nov 24, 2021
- Dov Bergwerk · Acting Chief Legal Officer · since Oct 13, 2023
- Brian Savage · Interim Chief Legal Officer · since Feb 11, 2026
- Matthew Shields · EVP, Global Operations · since Jun 3, 2024
- Evan Lippman · EVP, Business Development · since Mar 31, 2025
- Richard Daniell · EVP, Europe Commercial · listed since Mar 2026
- Christine Fox · EVP, U.S. Commercial · listed since Mar 2026
- Eric A Hughes · "See ""Remarks""" · since Aug 1, 2022
- Placid Jover · "See ""Remarks""" · since Aug 1, 2024
- Mark Sabag · "See ""Remarks""" · listed since Feb 2025
Changes in the last 10 years (62)
| Mar 6, 2026 | Christine Fox listed as EVP, U.S. Commercial (previously EVP, Head of U.S. Commercial) in SEC filings |
| Mar 5, 2026 | Richard Daniell listed as EVP, Europe Commercial (previously Exec. VP, European Commercial) in SEC filings |
| Feb 11, 2026 | Brian Savage became Interim Chief Legal Officer |
| Mar 31, 2025 | Evan Lippman became EVP, Business Development |
| Feb 14, 2025 | Mark Sabag listed as "See ""Remarks""" (previously EVP, International Markets) in SEC filings |
| Dec 1, 2024 | Chen Lichtenstein became a director |
| Aug 1, 2024 | Placid Jover became "See ""Remarks""" |
| Jun 3, 2024 | Matthew Shields became EVP, Global Operations |
| May 15, 2024 | The company announced the departure of Eric Drape as Executive VP Global Operations in an SEC filing |
| Mar 4, 2024 | David R. McAvoy became EVP, Chief Legal Officer |
| Nov 20, 2023 | Christine Fox became EVP, Head of U.S. Commercial |
| Oct 13, 2023 | Dov Bergwerk became Acting Chief Legal Officer |
| Sep 25, 2023 | Vikki L Conway became "See ""Remarks""" |
| Sep 25, 2023 | The company announced the departure of Sven Dethlefs as EVP, North America Commercial in an SEC filing |
| Sep 1, 2023 | Varda Shalev became a director |
| Aug 1, 2023 | Angus Grant became EVP, Business Development |
| May 8, 2023 | The company announced the departure of Jean Michel Halfon from the board in an SEC filing |
| Jan 1, 2023 | Richard D Francis became President and CEO |
| Nov 18, 2022 | The company announced the departure of Kare Schultz from the board in an SEC filing |
| Nov 18, 2022 | The company announced the departure of Kare Schultz as President and CEO in an SEC filing |
| Aug 1, 2022 | Eric A Hughes became "See ""Remarks""" |
| Feb 24, 2022 | The company announced the departure of Hafrun Fridriksdottir as Executive VP, Global R&D in an SEC filing |
| Feb 10, 2022 | Sven Dethlefs listed as EVP, North America Commercial (previously EVP Global Marketing&Portfolio) in SEC filings |
| Feb 10, 2022 | Mark Sabag listed as EVP, International Markets (previously "See ""Remarks"" below") in SEC filings |
| Nov 24, 2021 | Amir Weiss became Chief Accounting Officer |
| Nov 22, 2021 | The company announced the departure of Andrew Weil as Chief Accounting Officer in an SEC filing |
| Oct 1, 2021 | Tal Zvi Zaks became a director |
| Aug 15, 2021 | Galia Inbar became "See ""Remarks""" |
| Aug 15, 2021 | Eli Shani became EVP,Global Marketing&Portfolio |
| Feb 15, 2021 | Andrew Weil became Chief Accounting Officer |
| Sep 1, 2020 | Abbas Hussain became a director |
| Jun 9, 2020 | Janet S. Vergis became a director |
| Mar 3, 2020 | Gianfranco Nazzi listed as EVP, International Markets (previously EVP, Growth Markets Commercial) in SEC filings |
| Feb 11, 2020 | Mark Sabag listed as "See ""Remarks"" below" (previously EVP, Global Human Resources) in SEC filings |
| Dec 22, 2019 | Eliyahu Sharon Kalif became EVP, Chief Financial Officer |
| Oct 2, 2019 | Eric Drape became Executive VP Global Operations |
| Jun 5, 2018 | Ronit Satchi-Fainaro became a director |
| Feb 12, 2018 | Kare Schultz first listed as a director in an SEC filing |
| Feb 6, 2018 | Mark Sabag became EVP, Global Human Resources |
| Feb 6, 2018 | Iris Beck Codner became EVP Global Brand&Communication |
| Jan 1, 2018 | Sven Dethlefs became EVP Global Marketing&Portfolio |
| Jan 1, 2018 | Sol J Barer became a director |
| Jan 1, 2018 | Rosemary A Crane became a director |
| Jan 1, 2018 | Roberto Mignone became a director |
| Jan 1, 2018 | Richard Daniell became Exec. VP, European Commercial |
| Jan 1, 2018 | Perry Nisen became a director |
| Jan 1, 2018 | Nechemia Jacob Peres became a director |
| Jan 1, 2018 | Murray A Goldberg became a director |
| Jan 1, 2018 | Michael James McClellan became EVP, Chief Financial Officer |
| Jan 1, 2018 | Kare Schultz became President and CEO |
| Jan 1, 2018 | Jean Michel Halfon became a director |
| Jan 1, 2018 | Hafrun Fridriksdottir became Executive VP, Global R&D |
| Jan 1, 2018 | Gianfranco Nazzi became EVP, Growth Markets Commercial |
| Jan 1, 2018 | Gerald M Lieberman became a director |
| Jan 1, 2018 | Galia Maor became a director |
| Jan 1, 2018 | Gabrielle Greene-Sulzberger became a director |
| Jan 1, 2018 | Deborah A Griffin became Chief Accounting Officer |
| Jan 1, 2018 | David Matthew Stark became Exec. VP Chief Legal Officer |
| Jan 1, 2018 | Dan S Suesskind became a director |
| Jan 1, 2018 | Carlo de Notaristefani became Executive VP Global Operations |
| Jan 1, 2018 | Brendan P. O'Grady became EVP, North America Commercial |
| Jan 1, 2018 | Amir Elstein became a director |
Not reported recently (18)
- David R. McAvoy · Last reported as EVP, Chief Legal Officer in an SEC filing dated Sep 9, 2025
- Angus Grant · Last reported as EVP, Business Development in an SEC filing dated Aug 13, 2024
- Vikki L Conway · Last reported as "See ""Remarks""" in an SEC filing dated May 15, 2024
- David Matthew Stark · Last reported as Exec. VP Chief Legal Officer in an SEC filing dated Mar 8, 2023
- Eli Shani · Last reported as EVP,Global Marketing&Portfolio in an SEC filing dated Mar 7, 2023
- Galia Inbar · Last reported as "See ""Remarks""" in an SEC filing dated Mar 7, 2023
- Nechemia Jacob Peres · Last reported as a director in an SEC filing dated Aug 8, 2022
- Abbas Hussain · Last reported as a director in an SEC filing dated Jun 16, 2021
- Brendan P. O'Grady · Last reported as EVP, North America Commercial in an SEC filing dated Mar 8, 2021
- Gianfranco Nazzi · Last reported as EVP, International Markets in an SEC filing dated Mar 8, 2021
- Deborah A Griffin · Last reported as Chief Accounting Officer in an SEC filing dated Mar 19, 2020
- Michael James McClellan · Last reported as EVP, Chief Financial Officer in an SEC filing dated Nov 6, 2019
- Murray A Goldberg · Last reported as a director in an SEC filing dated Jun 13, 2019
- Carlo de Notaristefani · Last reported as Executive VP Global Operations in an SEC filing dated May 21, 2019
- Iris Beck Codner · Last reported as EVP Global Brand&Communication in an SEC filing dated Mar 6, 2019
- Dan S Suesskind · Last reported as a director in an SEC filing dated Feb 12, 2018
- Gabrielle Greene-Sulzberger · Last reported as a director in an SEC filing dated Jan 2, 2018
- Galia Maor · Last reported as a director in an SEC filing dated Jan 2, 2018
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
TEVA Proposed Insider Sales (Form 144)
Latest: 2026-09-21
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
5 filings
· $16.7M notice value
· 5 unique filers
· 60% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Bridger Management, LLC (1) (1, $14.4M) · Hughes Eric A (1, $892K) · Lippman Evan (1, $680K) · Jover Placid (1, $447K) · Savage Brian (1, $273K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-21 | Savage Brian | Officer, CHIEF LEGAL OFFICER | 7,028 | $273.1K | 2026-09-18 | CITIGROUP GLOBAL MARKETS | — | EDGAR |
| 2026-09-18 | Bridger Management, LLC (1) | Shareholder | 367,600 | $14.41M | 2026-09-18 | Apex Clearing Corporation | — | EDGAR |
| 2026-08-17 | Lippman Evan | Officer, EVP BUSINESS DEVELOPMENT | 18,600 | $680.3K | 2026-08-17 | CITIGROUP GLOBAL MARKETS | 10b5-1 | EDGAR |
| 2026-08-03 | Hughes Eric A | Executive VP Global R&D and Chief Med Officer | 25,578 | $892.1K | 2026-08-03 | Citigroup Global Markets, Inc | 10b5-1 | EDGAR |
| 2026-08-03 | Jover Placid | Executive VP, Chief HR Officer | 12,827 | $447.4K | 2026-08-03 | Citigroup Global Markets, Inc | 10b5-1 | EDGAR |
| 2026-06-18 | Shields Matthew | Officer, EXECUTIVE VP TEVA GLOBAL OPERATIONS | 9,989 | $321.5K | 2026-06-18 | CITIGROUP GLOBAL MARKETS | — | EDGAR |
| 2026-06-11 | Kalif Eliyahu Sharon | Officer, EVP CHIEF FINANCIAL OFFICER | 106,563 | $3.63M | 2026-06-11 | CITIGROUP GLOBAL MARKETS | 10b5-1 | EDGAR |
| 2026-06-05 | Francis Richard D | Officer, PRESIDENT AND CEO | 6,153 | $211.4K | 2026-06-05 | CITIGROUP GLOBAL MARKETS INC | 10b5-1 | EDGAR |
| 2026-06-03 | Shields Matthew | Officer, EXECUTIVE VP TEVA GLOBAL OPERATIONS | 16,195 | $532.3K | 2026-06-03 | CITIGROUP GLOBAL MARKETS | 10b5-1 | EDGAR |
| 2026-05-14 | Lippman Evan | Officer, EXECUTIVE VP BUSINESS DEVELOPMENT | 41,658 | $1.48M | 2026-05-14 | CITIGROUP GLOBAL MARKETS | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
86 ETFs hold TEVA
25 shown · $2.56B total exposure · 0.23% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VXUS Vanguard Total International Stock ETF | Vanguard | 0.10% | $682.0M | — | 2026-09-30 |
| 2 | VEA Vanguard FTSE Developed Markets ETF | Vanguard | 0.14% | $450.1M | — | 2026-09-30 |
| 3 | IEFA iShares Core MSCI EAFE ETF | iShares (BlackRock) | 0.19% | $353.7M | $190.1B | 2026-10-26 |
| 4 | EFA iShares MSCI EAFE ETF | iShares (BlackRock) | 0.22% | $167.0M | $76.8B | 2026-10-26 |
| 5 | VEU Vanguard FTSE All-World Ex-US ETF | Vanguard | 0.11% | $109.8M | — | 2026-09-30 |
| 6 | EIS iShares MSCI Israel ETF | iShares (BlackRock) | 11.33% | $100.2M | $898.5M | 2026-10-26 |
| 7 | WCMI First Trust WCM International Equity ETF | First Trust | 3.86% | $79.7M | $2.1B | 2026-10-26 |
| 8 | EFG iShares MSCI EAFE Growth ETF | iShares (BlackRock) | 0.45% | $66.6M | $15.1B | 2026-10-26 |
| 9 | IXUS iShares Core MSCI Total International Stock ETF | iShares (BlackRock) | 0.11% | $64.2M | $57.6B | 2026-10-26 |
| 10 | IDEV iShares Core MSCI International Developed Markets ETF | iShares (BlackRock) | 0.17% | $57.0M | $34.0B | 2026-10-26 |
| 11 | SPDW State Street® SPDR® Portfolio Developed World ex-US ETF | SPDR (State Street) | 0.14% | $55.9M | $40.7B | 2026-10-26 |
| 12 | PPH VanEck Pharmaceutical ETF | VanEck | 4.57% | $48.2M | $1.1B | 2026-10-26 |
| 13 | IDVO Amplify CWP International Enhanced Dividend Income ETF | Amplify | 3.43% | $48.0M | $1.4B | 2026-10-27 |
| 14 | VT Vanguard Total World Stock ETF | Vanguard | 0.04% | $40.0M | — | 2026-09-30 |
| 15 | FNDF Schwab Fundamental International Equity ETF | Nport | 0.14% | $34.8M | — | 2026-05-31 |
| 16 | IQLT iShares MSCI Intl Quality Factor ETF | iShares (BlackRock) | 0.22% | $30.4M | $13.7B | 2026-10-26 |
| 17 | IDMO Invesco S&P International Developed Momentum ETF | Invesco | 0.64% | $26.8M | — | 2026-10-26 |
| 18 | ACWX iShares MSCI ACWI ex U.S. ETF | iShares (BlackRock) | 0.13% | $23.3M | $17.9B | 2026-10-26 |
| 19 | IVLU iShares MSCI Intl Value Factor ETF | iShares (BlackRock) | 0.48% | $21.6M | $4.5B | 2026-10-26 |
| 20 | AVDE Avantis International Equity ETF | Avantis | 0.10% | $20.2M | $19.4B | 2026-10-26 |
| 21 | ESGD iShares ESG Aware MSCI EAFE ETF | iShares (BlackRock) | 0.16% | $18.4M | $11.9B | 2026-10-26 |
| 22 | DBEF Xtrackers MSCI EAFE Hedged Equity ETF | Nport | 0.18% | $16.3M | — | 2026-05-29 |
| 23 | IMTM iShares MSCI Intl Momentum Factor ETF | iShares (BlackRock) | 0.38% | $15.5M | $4.2B | 2026-10-26 |
| 24 | ACWI iShares MSCI ACWI ETF | iShares (BlackRock) | 0.05% | $15.0M | $32.8B | 2026-10-26 |
| 25 | ISRA VanEck Israel ETF | VanEck | 7.81% | $12.5M | $159.5M | 2026-10-26 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$1.20
TTM Revenue
$17.26B
TTM Net Income
$1.41B
TTM Op. Cash Flow
$1.65B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q4 '25 | 2025-12-31 | $4.71B | $480.00M | $0.41 | $1.16B |
| Q3 '25 | 2025-09-30 | $4.48B | $433.00M | $0.37 | $369.00M |
| Q2 '25 | 2025-06-30 | $4.18B | $282.00M | $0.24 | $227.00M |
| Q1 '25 | 2025-03-31 | $3.89B | $214.00M | $0.18 | $-105.00M |
| Q4 '24 | 2024-12-31 | $4.23B | $-217.00M | $-0.19 | $575.00M |
| Q3 '24 | 2024-09-30 | $4.33B | $-437.00M | $-0.39 | $693.00M |
| Q2 '24 | 2024-06-30 | $4.16B | $-846.00M | $-0.75 | $104.00M |
| Q1 '24 | 2024-03-31 | $3.82B | $-139.00M | $-0.12 | $-124.00M |
| Q4 '23 | 2023-12-31 | $4.46B | $463.00M | $0.41 | $1.18B |
| Q3 '23 | 2023-09-30 | $3.85B | $69.00M | $0.06 | $5.00M |
| Q2 '23 | 2023-06-30 | $3.88B | $-872.00M | $-0.78 | $324.00M |
| Q1 '23 | 2023-03-31 | $3.66B | $-220.00M | $-0.20 | $-145.00M |
Q4 2025 • period ending 2025-12-31 • filed 2026-02-03
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
33.66
P/B
5.93
P/S
2.72
EV/EBITDA
11.81
EV/Sales
3.38
ROE
17.8%
ROA
3.5%
Div Yield
0.00%
FCF Yield
3.51%
Debt/Equity
1.89
Current Ratio
—
Market Cap
$46.92B
as of 2026-10-27
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
29.85M
SI % of Float
2.57%
Days to Cover
5.40
Short Vol Ratio
23.4%
Free Float
1.16B
Float %
99.6%
Short interest 2026-09-30 • Short volume 2026-10-27 • Float 2026-08-05